home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
DP Tool Club 17
/
CD_ASCQ_17_101194.iso
/
vrac
/
med9408d.zip
/
M9480724.TXT
< prev
next >
Wrap
Text File
|
1994-08-27
|
4KB
|
56 lines
Document 0724
DOCN M9480724
TI Neutralizing antibodies to HIV-1 in seronegative volunteers immunized
with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine
Clinical Trials Network [see comments]
DT 9410
AU Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews
T; Weinhold K; Bolognesi DP; Sposto R; et al; Department of Medicine, St
Louis University School of Medicine,; MO 63104.
SO JAMA. 1994 Aug 10;272(6):475-80. Unique Identifier : AIDSLINE
MED/94315727
CM Comment in: JAMA 1994 Aug 10;272(6):488-9
AB OBJECTIVE--To evaluate the safety and immunogenicity of the MN strain of
recombinant gp120 (MN rgp120) as a vaccine prototype to prevent human
immunodeficiency virus (HIV). DESIGN--Double-blind, randomized,
placebo-controlled study with subjects vaccinated at 0, 4, 24, and 48
weeks and followed up through 64 weeks. SETTING--The AIDS Vaccine
Evaluation Units in St Louis, Mo, Nashville, Tenn, and Rochester, NY,
conducted the clinical study. Laboratory studies were conducted at Duke
University, Raleigh, NC; data analysis was done by the Data Coordinating
and Analysis Center at the EMMES Corporation, Potomac, Md.
PARTICIPANTS--Fifty-seven persons seronegative for HIV, at low risk for
acquiring HIV infection, and 18 to 60 years of age. INTERVENTIONS--The
MN rgp120 vaccine was administered to 12 volunteers each in doses of 100
micrograms, 300 micrograms, or 600 micrograms, and 12 volunteers
received a combination of 300 micrograms of MN rgp120 vaccine and 300
micrograms of vaccine from rgp120 of strain IIIB. Nine volunteers
received alum adjuvant alone (control). MAIN OUTCOME MEASURES--Safety
was assessed by monitoring lymphocyte subsets, serum creatinine, and
liver enzymes. Immunogenicity was measured by enzyme-linked
immunosorbent assay using the immunogen and synthetic peptide
corresponding to the variable region 3 domain of gp120. Functional
antibody assays included CD4 binding blocking; antibody-dependent,
cell-mediated cytotoxicity; and neutralization of homologous and
heterologous HIV strains. RESULTS--No severe adverse reactions occurred.
In 33 of 48 volunteers, two doses of vaccine induced antibodies that
neutralized the homologous strain HIV-1/MN. Three doses of vaccine
induced antibodies that neutralized MN (in 46 of 48 volunteers), SF-2
(in 45 of 48 volunteers), or IIIB strains of HIV-1 (in 30 of 48
volunteers). CONCLUSION--The vaccines were safe and immunogenic.
Multiple injections of vaccine broadened and increased the neutralizing
antibody response.
DE Adult Aged Antibody Affinity AIDS Vaccines/ADMINISTRATION &
DOSAGE/*IMMUNOLOGY/PHARMACOLOGY Dose-Response Relationship, Immunologic
Double-Blind Method Human HIV Antibodies/*IMMUNOLOGY HIV Envelope
Protein gp120/ADMINISTRATION & DOSAGE/*IMMUNOLOGY/ PHARMACOLOGY HIV
Infections/*PREVENTION & CONTROL HIV Seronegativity/*IMMUNOLOGY
HIV-1/*IMMUNOLOGY Leukocyte Count Middle Age Neutralization Tests
Peptide Fragments Recombinant Proteins/IMMUNOLOGY/PHARMACOLOGY
Support, U.S. Gov't, P.H.S. T4 Lymphocytes *Vaccination CLINICAL
TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).